Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 375 participants.
Also called NCT04251156
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 375 participants
- Sponsor
- Registry
-
NCT04251156
-
- Other papers using this trial's data
- Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Brazil, China, Hong Kong SAR China, South Korea
- Registry status
- Completed
Technical summary
Registry record NCT04251156. Randomized; quadruple masking; primary purpose treatment. Start 2020-12-08 (actual); primary completion 2022-08-23 (actual). Results posted on 2024-11-29.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.
- Acronym
- STEP7
- Condition
- Overweight
- Condition
- Obesity
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Placebo (semaglutide)
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct04251156- Content hash
f1e4868244e99dbd6dcc9319130def8935f82d1860d6b95def96e06847ebf400